EU/3/18/2009

Table of contents

About

On 16 April 2018, orphan designation (EU/3/18/2009) was granted by the European Commission to SOTIO a.s, Czech Republic, for autologous dendritic cells pulsed with killed ovarian cancer cells and matured by TLR3 ligand ex vivo (also known as DCVAC/OvCa) for the treatment of ovarian cancer.

Key facts

Active substance
autologous dendritic cells pulsed with killed ovarian cancer cells and matured by TLR3 ligand ex vivo
Disease / condition
Treatment of ovarian cancer
Date of decision
16/04/2018
Outcome
Positive
Orphan decision number
EU/3/18/2009

Sponsor's contact details

SOTIO a.s
Jankovcova 1518/2
Prague 7
170 00
Czech Republic
Tel. +420 224 175 111
E-mail: sotio@sotio.com

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe;
  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

How useful was this page?

Add your rating